The role of small intestinal permeability and gut microbiota in chronic liver disease

Author(s):  
Ashok Raj
2019 ◽  
Vol 10 (8) ◽  
pp. e00068 ◽  
Author(s):  
Ashok S. Raj ◽  
Erin R. Shanahan ◽  
Cuong D. Tran ◽  
Purnima Bhat ◽  
Linda M. Fletcher ◽  
...  

2020 ◽  
Vol 22 (1) ◽  
pp. 199
Author(s):  
Na Young Lee ◽  
Ki Tae Suk

Liver cirrhosis is one of the most prevalent chronic liver diseases worldwide. In addition to viral hepatitis, diseases such as steatohepatitis, autoimmune hepatitis, sclerosing cholangitis and Wilson’s disease can also lead to cirrhosis. Moreover, alcohol can cause cirrhosis on its own and exacerbate chronic liver disease of other causes. The treatment of cirrhosis can be divided into addressing the cause of cirrhosis and reversing liver fibrosis. To this date, there is still no clear consensus on the treatment of cirrhosis. Recently, there has been a lot of interest in potential treatments that modulate the gut microbiota and gut-liver axis for the treatment of cirrhosis. According to recent studies, modulation of the gut microbiome by probiotics ameliorates the progression of liver disease. The precise mechanism for relieving cirrhosis via gut microbial modulation has not been identified. This paper summarizes the role and effects of the gut microbiome in cirrhosis based on experimental and clinical studies on absorbable antibiotics, probiotics, prebiotics, and synbiotics. Moreover, it provides evidence of a relationship between the gut microbiome and liver fibrosis.


2016 ◽  
Vol 22 ◽  
pp. 2144-2151 ◽  
Author(s):  
Sandra Milic ◽  
Ivana Mikolasevic ◽  
Lidija Orlic ◽  
Edita Devcic ◽  
Nada Starcevic-Cizmarevic ◽  
...  

2020 ◽  
Vol 40 (02) ◽  
pp. 180-188 ◽  
Author(s):  
Christine E. Dolin ◽  
Gavin E. Arteel

AbstractChronic fatty liver disease is common worldwide. This disease is a spectrum of disease states, ranging from simple steatosis (fat accumulation) to inflammation, and eventually to fibrosis and cirrhosis if untreated. The fibrotic stage of chronic liver disease is primarily characterized by robust accumulation of extracellular matrix (ECM) proteins (collagens) that ultimately impairs the function of the organ. The role of the ECM in early stages of chronic liver disease is less well-understood, but recent research has demonstrated that several changes in the hepatic ECM in prefibrotic liver disease are not only present but may also contribute to disease progression. The purpose of this review is to summarize the established and proposed changes to the hepatic ECM that may contribute to inflammation during earlier stages of disease development, and to discuss potential mechanisms by which these changes may mediate the progression of the disease.


Hepatology ◽  
1999 ◽  
Vol 29 (3) ◽  
pp. 883-888 ◽  
Author(s):  
Thomas R. Frieden ◽  
Lisa Ozick ◽  
Colin McCord ◽  
Omana V. Nainan ◽  
Sara Workman ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document